10Dec
10Dec
Disruptive tech for vision-impaired: Gregory Ogorek, COO & president of eSight
Vision impairment and blindness caused by diseases such as glaucoma and age-related macular degeneration (AMD) is a concern and potential threat to the economy for Asia, as the population is rapidly aging. eSight, a Canadian startup providing wearable devices to help restore or enhance the vision of people with low vision, is planning to expand to Asia by leveraging Taiwan as a platform for R&D and manufacturing for the region. Read more >>
09Dec
Pixability Hires Industry Veteran John Danby To Lead Its European Operations
Pixability (www.pixability.com), the only provider of software and insights for video advertising on YouTube, YouTube on TV, Amazon Fire, Roku, and Hulu today announces the appointment of John Danby as Managing Director of the company's European operations. The appointment comes at a time when Pixability's European business has grown considerably. Read more >>
09Dec
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Read more >>
09Dec
Zylö Therapeutics receives $300K investment from SC Launch
SC Launch Inc., South Carolina Research Authority (SCRA’s) investment affiliate, announced Dec. 7 it has invested $300,000 in Zylö Therapeutics Inc., a medical research business in Greenville. Read more >>
08Dec
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit.
08Dec
ZetrOZ Proudly Continues Sponsorship of Connecticut Whale Women’s Ice Hockey
ZetrOZ Systems, developer of the sam® sustained acoustic medicine device, is proud to announce its continued support of Danbury's professional women's ice hockey team, the Connecticut Whale of the Premier Hockey Federation. For the second consecutive year, ZetrOZ is supporting the Whale and women's hockey with its wearable ultrasound technology that revolutionizes soft tissue injury healing. The ZetrOZ pain relief ultrasound device delivers long-duration slow-release ultrasound and promotes healing without the need for potentially addictive painkillers or invasive surgery.
07Dec
SMU and University of Virginia to play in Inaugural Wasabi Fenway Bowl
The SMU Mustangs and University of Virginia (UVA) Cavaliers will play each other in the inaugural Wasabi Fenway Bowl at Fenway Park on Wednesday, December 29 at 11 a.m. “The Wasabi Fenway Bowl will be a new landmark sporting tradition New England can be proud of, and we could not be more excited to have these two outstanding teams participating in the inaugural game at historic Fenway Park on December 29,” said Michael Welts, CMO of Wasabi Technologies. Read...
07Dec
SC Launch, Inc. Announces Third Investment in Zylö Therapeutics
South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch, Inc. has made its third investment into Zylö Therapeutics, Inc. This $300,000 investment will help the company continue providing therapeutic topical solutions. Read more >>
05Dec